Journal: Leukemia

Article Title: Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL).

doi: 10.1038/sj.leu.2403778

Figure Lengend Snippet: Figure 1 Representative immunoblots showing chromsome 12 candidate gene expression in CLL samples and cell lines (JVM-2, EHEB, JURKAT). Karyotype and VH mutation status (u ¼ unmutated VH; m ¼ mutated VH; nd ¼ not done) are highlighted. Each lane was loaded with 20 mg of total protein. (a) MDM-2 shows a specific pattern for each of the cell lines and restriction of expression to p90 and p57 in CLL samples. (b) Lower expression of STAT6 in JURKAT as compared to CLL samples, JVM-2 and EHEB. (c) Higher expression of p27 in CLL samples as well as in JURKAT when compared to JVM-2 and EHEB. No difference of p27 expression was detected between the CLL subgroups with or without trisomy 12 and mutated or umutated VH. (d) Restriction of CCND2 expression to JVM-2 and EHEB. (e) Lower expression of CDK2 (not shown) and CDK4 in CLL irrespective of the karyotype when compared to the cell lines. (f) Smac/DIABLO shows a double band in JVM-2 and a uniformly high expression in the genetic CLL subgroups. (g) No differences in ARF3 expression neither when comparing CLL cases with cell lines nor among the cell lines or CLL cases. Similar results were seen for APAF-1 and GLI (not shown). (h) Low but detectable expression and subtle differences in expression levels of AID, which were independent of the VH mutation status in the CLL samples.

Article Snippet: The human lymphoma cell lines EHEB (Epstein–Barr virus (EBV)transformed CLL), JVM-2 (EBV-transformed B-PLL/leukemic mantle cell lymphoma) and JURKAT (non-EBV-transformed T-ALL) were purchased from DSMZ (Braunschweig, Germany) and cultured in RPMI 1640 (Seromed, Berlin, Germany) supplemented with 10% fetal calf serum (Serva, Heidelberg, Germany).

Techniques: Western Blot, Gene Expression, Mutagenesis, Expressing

Journal: Leukemia

Article Title: Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL).

doi: 10.1038/sj.leu.2403778

Figure Lengend Snippet: Figure 2 Immunoblots showing chromosome 12 candidate gene expression in CD19 þ -B-cells (lane 3). To allow comparison with the results shown in Figure 1, two CLL samples as well as JVM-2 and EHEB were included. Each lane was loaded with 20 mg of total protein. (a) Lack of STAT6 expression in CD19 þ -B-cells. (b) No p27 expression in CD19 þ -B-cells. Detection of a higher p27 expression in the EHEB cell sample used for the experiment series shown in Figure 2 when compared with the sample used for the experiment series shown in Figure 1. (c) No difference in expression of CCND2 between CLL samples and CD19 þ -B-cells. Lower expression of CCND2 in the EHEB cell sample than in the first experiment series. (d and e) CD19 þ -B-cells and CLL samples with the same expression levels of ARF3, AID and CDK2. In contrast, the expression level of CDK4 is slightly higher in CLL than in CD19 þ -B-cells, but still significantly lower than in JVM-2 and EHEB. (f) Lower expression of Smac/DIABLO in CD19 þ -B-cells when compared to CLL cases. A double band is observed in JVM-2. (g) Similar expression level of APAF-1 in CLL, CD19 þ -B-cells and cell lines.

Article Snippet: The human lymphoma cell lines EHEB (Epstein–Barr virus (EBV)transformed CLL), JVM-2 (EBV-transformed B-PLL/leukemic mantle cell lymphoma) and JURKAT (non-EBV-transformed T-ALL) were purchased from DSMZ (Braunschweig, Germany) and cultured in RPMI 1640 (Seromed, Berlin, Germany) supplemented with 10% fetal calf serum (Serva, Heidelberg, Germany).

Techniques: Western Blot, Gene Expression, Comparison, Expressing

Journal: Leukemia

Article Title: Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL).

doi: 10.1038/sj.leu.2403778

Figure Lengend Snippet: Figure 1 Representative immunoblots showing chromsome 12 candidate gene expression in CLL samples and cell lines (JVM-2, EHEB, JURKAT). Karyotype and VH mutation status (u ¼ unmutated VH; m ¼ mutated VH; nd ¼ not done) are highlighted. Each lane was loaded with 20 mg of total protein. (a) MDM-2 shows a specific pattern for each of the cell lines and restriction of expression to p90 and p57 in CLL samples. (b) Lower expression of STAT6 in JURKAT as compared to CLL samples, JVM-2 and EHEB. (c) Higher expression of p27 in CLL samples as well as in JURKAT when compared to JVM-2 and EHEB. No difference of p27 expression was detected between the CLL subgroups with or without trisomy 12 and mutated or umutated VH. (d) Restriction of CCND2 expression to JVM-2 and EHEB. (e) Lower expression of CDK2 (not shown) and CDK4 in CLL irrespective of the karyotype when compared to the cell lines. (f) Smac/DIABLO shows a double band in JVM-2 and a uniformly high expression in the genetic CLL subgroups. (g) No differences in ARF3 expression neither when comparing CLL cases with cell lines nor among the cell lines or CLL cases. Similar results were seen for APAF-1 and GLI (not shown). (h) Low but detectable expression and subtle differences in expression levels of AID, which were independent of the VH mutation status in the CLL samples.

Article Snippet: The human lymphoma cell lines EHEB (Epstein–Barr virus (EBV)transformed CLL), JVM-2 (EBV-transformed B-PLL/leukemic mantle cell lymphoma) and JURKAT (non-EBV-transformed T-ALL) were purchased from DSMZ (Braunschweig, Germany) and cultured in RPMI 1640 (Seromed, Berlin, Germany) supplemented with 10% fetal calf serum (Serva, Heidelberg, Germany).

Techniques: Western Blot, Gene Expression, Mutagenesis, Expressing